Oncotelic Therapeutics (OTCQB: OTLC) Completes Strategic Asset Monetization with Lunai Bioworks
Key Developments Oncotelic Therapeutics (OTCQB: OTLC) has finalized a strategic asset transfer agreement involving its CNS/Nasal delivery platform with Lunai Bioworks, Inc. This deal focuses on advancing joint development efforts targeting biodefense applications and Alzheimer’s disease therapeutics. As part of the transaction, Oncotelic received $12.5 million worth of Lunai Bioworks Series B Convertible Preferred Stock. The company emphasized its ongoing commitment to exploring further partnerships that enhance monetization opportunities while…









